Document is current
Any future updates will be listed below
-
Authors
Kim, Myung-Chul
Borcherding, Nicholas
Ahmed, Kawther K. http://orcid.org/0000-0002-8526-0447
Voigt, Andrew P. http://orcid.org/0000-0001-8107-8317
Vishwakarma, Ajaykumar
Kolb, Ryan
Kluz, Paige N.
Pandey, Gaurav
De, Umasankar
Drashansky, Theodore http://orcid.org/0000-0001-6215-1232
Helm, Eric Y.
Zhang, Xin http://orcid.org/0000-0001-9751-7054
Gibson-Corley, Katherine N.
Klesney-Tait, Julia
Zhu, Yuwen http://orcid.org/0000-0003-1434-6590
Lu, Jinglu http://orcid.org/0000-0001-5606-575X
Lu, Jinsong
Huang, Xian
Xiang, Hongrui
Cheng, Jinke http://orcid.org/0000-0002-4344-5363
Wang, Dongyang
Wang, Zheng
Tang, Jian
Hu, Jiajia
Wang, Zhengting
Liu, Hua
Li, Mingjia
Zhuang, Haoyang
Avram, Dorina
Zhou, Daohong http://orcid.org/0000-0002-2400-6461
Bacher, Rhonda http://orcid.org/0000-0001-5787-476X
Zheng, Song Guo
Wu, Xuefeng http://orcid.org/0000-0002-6933-7280
Zakharia, Yousef http://orcid.org/0000-0001-9480-2626
Zhang, Weizhou http://orcid.org/0000-0002-8236-0346
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (CA203834)
- License Information
-
More Information
Article History
Received: 3 January 2020
Accepted: 17 September 2021
First Online: 1 October 2021
Competing interests
: X.Z. and D.Z. are inventors of two pending patent applications for the use of BCL-X<sub>L</sub> PROTACs as senolytic and antitumor agents. D.Z. is the co-founder of, and D.Z. and W.Z. have equity in, Dialectic Therapeutics, which develops BCL-X<sub>L</sub> PROTACs for the treatment of cancer. The other authors have no competing interests.
